Rekrutierende Studie = ; Fortlaufende Studie = ; Förderung durch ein IRDiRC-Mitglied = ; ERN-Mitglied =

Nationale klinische Studie(n)

OSTERREICH

STEIERMARK
GRAZ

OPA1: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation

Medizinische Universität Graz

Universitäts-Augenklinik

Mehr Details

VEREINIGTES KONIGREICH

Tyne & Wear
NEWCASTLE-UPON-TYNE

Phase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease

Faculty of Medical Sciences Newcastle University

Institute for Ageing and Health

Mehr Details

VEREINIGTES KONIGREICH

West Yorkshire
LEEDS

A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease-GB

Covance Clinical Research

Mehr Details